Aditxt (ADTX) Revenue & Revenue Breakdown
Aditxt Revenue Highlights
Latest Revenue (Y)
$645.18K
Latest Revenue (Q)
$44.28K
Aditxt Revenue by Period
Aditxt Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $645.18K | -30.90% |
| 2022-12-31 | $933.72K | 788.96% |
| 2021-12-31 | $105.03K | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Aditxt generated $645.18K in revenue during NA 2023, up -30.90% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Aditxt Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $44.28K | -44.43% |
| 2024-03-31 | $79.68K | -1.99% |
| 2023-12-31 | $81.30K | -34.69% |
| 2023-09-30 | $124.49K | -43.67% |
| 2023-06-30 | $220.98K | 1.17% |
| 2023-03-31 | $218.41K | 17.68% |
| 2022-12-31 | $185.60K | -42.56% |
| 2022-09-30 | $323.13K | 50.49% |
| 2022-06-30 | $214.72K | 2.11% |
| 2022-03-31 | $210.28K | 100.20% |
| 2021-12-31 | $105.03K | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | - |
Aditxt generated $44.28K in revenue during Q2 2024, up -44.43% compared to the previous quarter, and up 20.27% compared to the same period a year ago.
Aditxt Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PSTV | Plus Therapeutics | $4.91M | - |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| ADTX | Aditxt | $645.18K | $44.28K |
| BDRX | Biodexa Pharmaceuticals | $381.00K | $41.50K |
| PALI | Palisade Bio | $250.00K | - |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| NRBO | NeuroBo Pharmaceuticals | $7.00K | - |
| PXMD | PaxMedica | - | - |
| REVB | Revelation Biosciences | - | - |
| HILS | Tharimmune | - | - |
| DRMA | Dermata Therapeutics | - | - |
| ALLR | Allarity Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| BWV | Onconetix | - | - |
ADTX Revenue FAQ
What is Aditxt’s yearly revenue?
Aditxt's yearly revenue for 2023 was $645.18K, representing a decrease of -30.90% compared to 2022. The company's yearly revenue for 2022 was $933.72K, representing an increase of 788.96% compared to 2021. ADTX's yearly revenue for 2021 was $105.03K, representing an increase of 100.00% compared to 2020.
What is Aditxt’s quarterly revenue?
Aditxt's quarterly revenue for Q2 2024 was $44.28K, a -44.43% decrease from the previous quarter (Q1 2024), and a -79.96% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $79.68K, a -1.99% decrease from the previous quarter (Q4 2023), and a -63.52% decrease year-over-year (Q1 2023). ADTX's quarterly revenue for Q4 2023 was $81.3K, a -34.69% decrease from the previous quarter (Q3 2023), and a -56.20% decrease year-over-year (Q4 2022).
What is Aditxt’s revenue growth rate?
Aditxt's revenue growth rate for the last 3 years (2021-2023) was 514.25%, and for the last 5 years (2019-2023) was 0%.